Ofman Joshua J., an insider at Grail Inc (GRAL), sold 368,818 shares of the company on December 2, 2025, at a price of $100.00 per share. This transaction totalled $36.88 million. Following the sale, Ofman retains 368,818 shares in the company.
Grail Inc operates as a commercial-stage healthcare company focused on the early detection of cancer. Headquartered in Menlo Park, California, the firm employs approximately 1,000 full-time staff. The company went public on June 12, 2024, and currently holds a market capitalization of $3.9 billion. Its multi-cancer early detection test, the Galleri test, is designed to identify multiple cancer types before symptoms appear, potentially improving treatment outcomes.
Insider selling can occur for various reasons, including diversification, tax planning, or personal financial needs. While significant selling may draw investor attention, it does not inherently reflect negative sentiment towards the company. It is important for investors to consider insider transactions as part of a broader analysis, examining patterns across multiple insiders and time periods rather than isolated events.
Grail Inc's upcoming earnings report is scheduled for May 11, 2026, with an estimated EPS of -3.08 and projected revenue of $38.3 million. This update provides insight into the company's financial health and insider activities, which investors may weigh alongside other fundamental and technical factors.